Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VI versus VIT for relapsed or refractory rhabdomyosarcoma
ISRCTN66172474Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Feb 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of vincristine, irinotecan and temozolomide in rhabdomyosarcoma (RMS) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Complete or partial tumour response. Started Feb 2012; status: completed.
02
Drugs
vincristineirinotecantemozolomide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on ISRCTN66172474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66172474.